CRBP Corbus Pharmaceuticals Holdings, Inc.: Earnings per share for the last 12 months

Corbus Pharma (CRBP) - corporate logo

Corbus Pharmaceuticals (CRBP) is implementing automated bioscreening systems to accelerate the discovery of anti-tumor compounds, confirming a market trend visualized in monetary terms with a value of -10.50. The business relies on synergy with leading global institutions for the joint testing of new treatment methods. In the future, the commercialization of effective drugs will enable the company to establish pricing power over insurance organizations.

Corbus Pharma (CRBP) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

CRBP (Corbus Pharmaceuticals Holdings, Inc.): analytical breakdowns and indicator data

Fundamental company valuation:CRBP Corbus Pharma
Flagship merchandise of Corbus Pharmaceuticals Holdings

Long-term investing requires strict monitoring of profit growth rates to avoid overpaying for an asset. Amidst the fierce race among biotech companies for drug approvals, the operational efficiency of Corbus Pharmaceuticals (CRBP) becomes a critical survival factor. By analyzing the YoY TTM earnings per share chart, an investor assesses EPS dynamics over the last twelve months relative to the previous year. Steady growth in this metric confirms the business's ability to generate value exceeding the cost of capital.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months